Get the Stockscreener App
1.30
7.44%
0.09
After Hours:
1.28
-0.02
-1.54%
Pyxis Oncology Inc stock is traded at $1.30, with a volume of 1.33M.
It is up +7.44% in the last 24 hours and down -69.19% over the past month.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
See More
Previous Close:
$1.21
Open:
$1.22
24h Volume:
1.33M
Relative Volume:
1.16
Market Cap:
$80.94M
Revenue:
-
Net Income/Loss:
$-73.79M
P/E Ratio:
-0.7065
EPS:
-1.84
Net Cash Flow:
$-77.44M
1W Performance:
+19.27%
1M Performance:
-69.19%
6M Performance:
+18.18%
1Y Performance:
-26.14%
1-Day Range:
$1.20
$1.34
1-Week Range:
$1.085
$1.34
52-Week Range:
$0.8332
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.30 | 75.34M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Goosehead Insurance Inc 2OX Stock Analysis and ForecastMomentum Trading Signals & Exceptional Return Capital - earlytimes.in
Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Pyxis Oncology Inc. stock positioned well for digital economyShort-Term Trading Alerts & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 57.3% - MarketBeat
Pyxis Oncology Stock Plunge: A Buy Signal? - StocksToTrade
Pyxis Oncology Stock Slides 73% With A 7-Day Losing Spree - Trefis
Is Pyxis Oncology Inc. stock recession proofExit Point & AI Forecasted Entry and Exit Points - Улправда
Will Pyxis Oncology Inc. stock benefit from automationEarnings Recap Summary & Weekly Setup with ROI Potential - Улправда
Bear Alert: Is Pyxis Oncology Inc. stock a contrarian buy2025 Year in Review & Safe Entry Momentum Stock Tips - Улправда
How Pyxis Oncology Inc. stock compares to growth peersQuarterly Profit Summary & Weekly High Conviction Trade Ideas - Улправда
Pyxis Oncology (NASDAQ:PYXS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Pyxis Oncology Stock 6-Day Losing Spree: Stock Falls 71% - Trefis
HC Wainwright & Co. Maintains Pyxis Oncology (PYXS) Buy Recommendation - Nasdaq
RBC Capital Maintains Pyxis Oncology (PYXS) Outperform Recommendation - Nasdaq
Pyxis Oncology sees cash runway into 4Q26 - MSN
Is Pyxis Oncology Inc. stock a dividend growth opportunity2025 Bull vs Bear & Long-Term Safe Return Strategies - DonanımHaber
Pyxis Oncology stock price target raised to $7 by H.C. Wainwright - Investing.com Nigeria
RBC Capital Lowers Price Target for Pyxis Oncology (PYXS) to $5, Maintains Outperform Rating | PYXS Stock News - GuruFocus
Analysts Sound Alarm On Pyxis Oncology's Tiny Trial - Benzinga
RBC Cuts Price Target on Pyxis Oncology to $5 From $8, Keeps Outperform, Speculative Risk - marketscreener.com
Pyxis plummets following phase 1 data on candidate for head and neck cancer - MSN
Is Pyxis Oncology Inc. stock a contrarian buy2025 Trade Ideas & Risk Adjusted Buy/Sell Alerts - Улправда
Pyxis Oncology Sees Unusually High Options Volume (NASDAQ:PYXS) - Defense World
Pyxis Oncology reports positive data for head and neck cancer drug By Investing.com - Investing.com South Africa
Fed Meeting: Is Pyxis Oncology Inc. stock positioned well for digital economyMarket Trend Report & AI Enhanced Trade Execution Alerts - Улправда
Pyxis Oncology stock falls as RBC cuts price target on complex trial data - Investing.com Australia
Pyxis Oncology stock falls as RBC cuts price target on complex trial data By Investing.com - Investing.com South Africa
Pyxis Oncology reports positive data for head and neck cancer drug - Investing.com Nigeria
Pyxis Oncology Stock (PYXS) Opinions on Phase 1 Cancer Drug Data - Quiver Quantitative
Stock Traders Buy Large Volume of Pyxis Oncology Put Options (NASDAQ:PYXS) - MarketBeat
Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell CarcinomaSlideshow (NASDAQ:PYXS) 2025-12-18 - Seeking Alpha
Transcript : Pyxis Oncology, Inc.Special Call - marketscreener.com
Pyxis Oncology stock plummets after early-stage cancer drug data By Investing.com - Investing.com South Africa
Pyxis Oncology stock plummets after early-stage cancer drug data - Investing.com
Pyxis Oncology’s Stock Moves: Time for Investors to Act? - timothysykes.com
PYXS: MICVO shows strong efficacy and safety in R/M HNSCC, both as monotherapy and with KEYTRUDA - TradingView — Track All Markets
Pyxis Oncology Reports Strong MICVO Data and Financing - TipRanks
Pyxis Oncology, Inc. Announces Positive Preliminary Phase 1 Data for MICVO - TradingView — Track All Markets
PYXS FinancialsIncome Statement - Quiver Quantitative
Pyxis Oncology (PYXS) shows promising MICVO results and extends cash runway - Stock Titan
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - The Manila Times
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):